ArticleJournal of the National Cancer Institute2019
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Gonadotropin-releasing hormone agonists during cyclophosphamide for ovarian protection in systemic lupus erythematosus.Reproduction & fertility · 2026Pooled it
- Interventions for fertility preservation in women with cancer undergoing chemotherapy.The Cochrane database of systematic reviews · 2025Pooled it
- Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.Journal of the National Cancer Institute · 2022Trial
- Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.Journal of the National Cancer Institute · 2021Trial
- The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial.Breast (Edinburgh, Scotland) · 2020Trial
- Nationwide Survey of Institutional Factors Related to the Use of Gonadotropin-Releasing Hormone Analogs for Ovarian Protection in Women Receiving Chemotherapy in Japan.The journal of obstetrics and gynaecology research · 2026Article
- Breast Cancer Surgical Risk Reduction, Fertility and Fertility Preservation for Current Breast Cancer Reports.Current breast cancer reports · 2026Review
- Risk Assessment and Fertility Counseling for Hereditary Gynecological Cancer Syndromes.Cancer medicine · 2025Review
- Tumor-associated macrophages-induced lncRNA RP11-627G18.1 promotes breast cancer metastasis.Genes and immunity · 2025Article
- [Impact of concurrent use of goserelin on the efficacy of neoadjuvant chemotherapy in young breast cancer patients].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Mechanism of GPR173-Mediated Suppression of TNBC Proliferation and Metastatic Potential via GnRHR Upregulation.Clinical Medicine Insights. Oncology · 2025Article
- Efficacy of goserelin in ovarian function suppression and preservation for pre- and perimenopausal breast cancer patients: a systematic review.Therapeutic advances in medical oncology · 2025Review
- Fertility in early breast cancer patients: integrating reproductive planning into oncology care.Frontiers in endocrinology · 2025Review
- Review
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- Article
- Review
- Ovarian Suppression: Early Menopause and Late Effects.Current treatment options in oncology · 2024Review
- Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.NPJ breast cancer · 2024Review
Corrections and comments
- Commented on by
Authors and funding
25 authors at 20 institutions in 6 countries.
Funding
Abstract
Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P = .03). Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P = .06). In this long-term analysis of POEMS/S0230, we found continued evidence that patients randomly assigned to receive goserelin + chemotherapy were not only more likely to avoid premature menopause, but were also more likely to become pregnant without adverse effect on disease-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.